Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer
Lasofoxifene plus abemaciclib is set to be evaluated in ESR1-mutated ER+/HER2– metastatic breast cancer in the phase 3 ELAINEIII trial.
Lasofoxifene plus abemaciclib is set to be evaluated in ESR1-mutated ER+/HER2– metastatic breast cancer in the phase 3 ELAINEIII trial.
An abstract is unavailable.
Practice of cancer precision medicine relies on availability of advanced molecular diagnostic tools to guide use of targeted therapies, which now comprise
‘We need a new language for talking about stage 4 cancer’ – Kate’s story
Kristien Borremans, PhD, KU Leuven, Louvain, Belgium, comments on how findings from assessing mRNA expression of antibody-drug conjugate (ADC) targets in normal and metastatic breast…
Atezolizumab combination therapy elicited better responses in patients with PD-L1 expression of 1% or more with EGFR-mutant NSCLC.
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.
Researchers found that prostate cancer patients with greater socioeconomic disadvantages were less likely to receive targeted therapy, and participation in the 340B program did not…
During the Lymphoma Hub Steering Committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on, How to treat older…
This live educational event is intended for learners to be better able to understand the dynamic data evaluating diagnostic and care strategies for hematopoi…
A new study highlights the link between visit-to-visit blood pressure variability (BPV) and cognitive decline in older adults. Read on!